menu
    • menu
    [{"orgOrder":0,"company":"Xiling Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xiling Lab \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OQL051","moa":"CDK4","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OQL051","moa":"CDK4","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SL-325","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SL-325","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Private Placement","leadProduct":"SL-325","moa":"DR3","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"NM-102","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"9 Meters Biopharma \/ Gustave Roussy","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Gustave Roussy"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Renexxion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naronapride","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renexxion \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Renexxion \/ Undisclosed"},{"orgOrder":0,"company":"Naval Medical Research Center","sponsor":"Immuron","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Naval Medical Research Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naval Medical Research Center \/ Immuron","highestDevelopmentStatusID":"5","companyTruncated":"Naval Medical Research Center \/ Immuron"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cellspan Esophageal Implant","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Undisclosed"},{"orgOrder":0,"company":"ISOThrive","sponsor":"Virginia Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Carbohydrate","year":"2020","type":"Funding","leadProduct":"Maltosyl-Isomaltooligosaccharide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"ISOThrive","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISOThrive \/ Virginia Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"ISOThrive \/ Virginia Catalyst"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossium Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Ossium Health \/ Undisclosed"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Neurenati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Genson Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Funding","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Neurenati Therapeutics \/ Genson Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Genson Capital"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Financing","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"Plakous Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Protego-PD","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Plakous Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plakous Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plakous Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Eventide Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Eventide Asset Management"}]

    Find FDA Investigational New Drug (IND) Submissions for Gastroenterology

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shattuck Labs

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Shattuck Labs

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $103.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Shattuck Labs Announces Closing of up to $103 Million Private Placement

                            Details : The proceeds from the financing will be used to advance SL-325 through multiple clinical milestones. Currently it is being evluated for the treatment of Inflammatory Bowel Disease.

                            Product Name : SL-325

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            August 26, 2025

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $103.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neurenati Therapeutics

                            Canada arrow
                            AllPack Indonesia
                            Not Confirmed

                            Neurenati Therapeutics

                            Canada arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan & Rare Pediatric Status to Neurenati’s NEU-001 for Hirschsprung

                            Details : NEU-001 is a first-in-class, once-in-a-lifetime treatment administered intrarectally, which is being evaluated to treat Hirschsprung's disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 04, 2025

                            Lead Product(s) : NEU-001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shattuck Labs

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Shattuck Labs

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shattuck Labs Shares Positive Data on SL-325 in IBD at ECCO 2025

                            Details : SL-325 is a first-in-class DR3 antagonist, currently being investigated for the treatment of inflammatory bowel diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shattuck Labs

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Shattuck Labs

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shattuck Labs Announces SL-325, a First-In-Class DR3 Antagonist, in TL1A/DR3 Pathway

                            Details : SL-325 is a first-in-class antagonist antibody to DR3, the receptor for TL1A, which is being evaluated for the treatment of inflammatory bowel disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 01, 2024

                            Lead Product(s) : SL-325

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jaguar Health

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Jaguar Health

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluatio...

                            Details : Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of short bowel syndrome.

                            Product Name : Mytesi

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            OnQuality Pharma

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            OnQuality Pharma

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OQL051

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OnQuality Announces FDA Clearance of IND Application for OQL051, for the Prophylaxis of Chemotherapy-Induced D...

                            Details : OQL051 sia first-in-disease, oral, gut-restricted CDK4/6 inhibitor – is designed to prevent the development of CID in patients receiving cytotoxic chemotherapies. The drug works by temporarily arresting the rapidly dividing intestinal mucosal cells in ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2023

                            Lead Product(s) : OQL051

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tryp Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Tryp Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical T...

                            Details : TRP-8802 (Oral psilocybin) in patients with Irritable Bowel Syndrome, represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with IBS.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            May 24, 2023

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Naval Medical Research Center

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Naval Medical Research Center

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Immuron

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial...

                            Details : CampETEC is a new therapeutic developed in collaboration with NMRC. Two Phase Il clinical studies are planned to evaluate safety and clinical efficacy against infectious diarrhea caused by Campylobacter and ETEC.

                            Product Name : CampETEC

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 08, 2023

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Immuron

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ExeGi

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            ExeGi

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXE-346

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ExeGi Pharma Announces Clearance of Investigational New Drug (IND) Application for EXE-346 a Live Biotherapeut...

                            Details : EXE-346 is a live biotherapeutic product (LBP) a blend of probiotic bacteria formulated in extremely high potency. The product is currently under development to manage excessive stool frequency in patients who have undergone an ileal pouch-anal anastomos...

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            January 26, 2023

                            Lead Product(s) : EXE-346

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Immuron

                            Australia arrow
                            AllPack Indonesia
                            Not Confirmed

                            Immuron

                            Australia arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeu...

                            Details : The Naval Medical Research Center (NMRC) has executed a research agreement with Immuron to develop and clinically evaluate a new therapeutic CampETEC, targeting Campylobacter and ETEC infections.

                            Product Name : CampETEC

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 25, 2023

                            Lead Product(s) : CampETEC

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth